ClinicalTrials.gg
Enrolling by invitationNCT05704309DPPOS-4Updated Aug 26, 2025

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

An observational study in Diabetes, Alzheimer Disease and Dementia, Vascular, sponsored by Marinella Temprosa. Enrolling by invitation at 27 sites in United States. Per ClinicalTrials.gov, last updated 2025-08-26.

Primary conditionPrediabetic StateRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Prediabetic State
Why
  1. The study's listed conditions name Prediabetic State, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Marinella Temprosa · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,976
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 390 studies in Prediabetic State with a site in United States — 83 open to participants now, 107 under way, 2 of them phase 3. Prediabetic State · United States.

Planned enrollment
5th of 28
1,976 · median 188
Started
2022
with 31 others
Observational
28 of 390
11 open now
Primary completion
2027-01
later than 34 of 106 live
Registered
271st of 390
by date

Among the 390 studies in Prediabetic State with a site in United States, this one is the 5th largest by planned enrollment of the 28 observational ones that give a count, is one of 32 that started in 2022, is one of 28 observational ones, reaches primary completion later than 34 of the 106 other live ones, and was the 271st registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

83 of the 390 studies in Prediabetic State with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Prediabetic State with a site in United States, or all of them as a file.
02

Study summary

The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for cognitive impairment and represent a large fraction of the United States (US) population? This U19 proposal addresses the National Alzheimer's Project Act goal to "prevent, halt, or reverse AD" in the high-risk group of persons with pre-diabetes and type 2 diabetes, who represent over half of the population aged 60 years and older in the US.

Read the detailed description

DPPOS AD/ADRD focuses on one of the most important, complex questions in Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) research: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for cognitive impairment and represent a large fraction of the United States (US) population? Despite knowledge that persons with PreD and T2D are a high-risk group for cognitive decline, mild cognitive impairment (MCI), and dementia, the risk factors, mechanisms, and neuropathology of cognitive impairment in persons with PreD and T2D remain unclear. Gaps in knowledge on cognitive impairment in PreD and T2D include: (a) the role of AD and/or non-AD neuropathology beyond vascular contributions to cognitive impairment and dementia (VCID); (b) the role of glycemia, related metabolic factors such as hyperinsulinemia, and traditional micro and macrovascular complications of PreD/T2D; (c) the role of glucose-lowering medications, primarily metformin; and (d) the role of physical activity, physical function, and frailty, key in PreD and T2D. The 4 interrelated projects will address these gaps, leveraging the Diabetes Prevention Program (DPP) Outcomes Study (DPPOS) cohort and its detailed PreD/T2D phenotyping, adding state of the art AD/ADRD phenotyping. The DPPOS cohort currently has a mean age of 72 years, with 76% over the age of 65. Thus, the cohort is in a period of the lifespan when the development of cognitive decline, MCI, and dementia accelerates. This extensively phenotyped cohort represents an estimated 50 million Americans. To address this proposal's complex interrelated questions, the study has two waves of state-of-the-art AD/ADRD phenotyping during the proposed 5-year funding period, including comprehensive cognitive assessments and syndrome adjudication and plasma and brain imaging biomarkers of AD/ADRD. The study will address the complex overarching question of our project through the following aims: (1) To establish 5 cores to support the 4 integrated scientific projects: An Administrative Core, a Clinical Operations and Procedures Core, a Cognitive Assessment and Adjudication Core, a Neuroimaging and Plasma Biomarkers Core, and A Biostatistics and Data Infrastructure Core: (2) To conduct 4 integrated projects focused on key aspects of the central question of this proposal: Project 1 will examine the association of cognitive decline, MCI, and dementia in the DPPOS cohort with biomarkers of neuropathology and brain insulin signaling, and with sociodemographic and behavioral factors; Project 2 will examine the associations of cumulative glycemia, related metabolic factors, and microvascular and macrovascular complications, with cognitive syndromes and biomarkers of neuropathology; Project 3 will examine the association of cumulative exposure to metformin and other T2D medications with cognitive syndromes and biomarkers of neuropathology; Project 4 will evaluate the association of trajectories of physical activity, physical function and frailty with cognitive syndromes and biomarkers of neuropathology.

03

Conditions studied

  • Diabetes
  • Alzheimer Disease
  • Dementia, Vascular
  • Dementia
  • PreDiabetes
04

In context

Prediabetic State Reclassified

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

This study's planned enrollment of 1,976 is above the median of 224 across 129 observational studies indexed under Prediabetic State.

Browse Prediabetic State studies →

Lead sponsor

This is the only study on the registry with Marinella Temprosa as lead sponsor.

Compared within Prediabetic State, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The DPPOS (2002-2022) is a 25-center observational study that started as the DPP randomized controlled clinical trial (1996-2001). The DPP demonstrated the ability to reduce the development of T2D with intensive lifestyle or metformin compared with placebo among persons with PreD. The combined DPP and DPPOS have followed the original DPP cohort for a mean of 23 (range 21-25) years as of 2022. For this project, we expect that the cohort will have 1979 participants, with approximately two thirds with T2D of precisely known duration. Forty-eight percent of the cohort are ethnic and racial minorities that are at relatively higher risk of AD/ADRD compared with non-Hispanic whites, and 71% are women.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All surviving participants originally randomized in the Diabetes Prevention Program
  • For Brain Imaging subcohort, only participants aged 55 years and older and those without to MRI will be included. Contraindications to MRI include the inability to lie flat, claustrophobia, and the presence of indwelling metallic objects, medical or non-medical, that are not 3T MRI compatible.

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,976 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Cognitive Diagnoses

    Classification of normal, mild cognitive impairment or dementia based on NACC UDS

    Time frame: Sept 2022 to October 2026

Secondary outcomes

  1. ptau-181

    Plasma biomarkers for AD/ADRD

    Time frame: Sept 2022 to October 2026

  2. Aβ42/40 ratio

    Plasma biomarkers for AD/ADRD

    Time frame: Sept 2022 to October 2026

  3. Neurofilament Light Chain (NfL)

    Plasma biomarkers for AD/ADRD

    Time frame: Sept 2022 to October 2026

  4. Glial fibrillary acidic protein (GFAP)

    Plasma biomarkers for AD/ADRD

    Time frame: Sept 2022 to October 2026

  5. Amnestic cognitive decline

    Based on the SEVLT immediate recall (sum of trials 1-3) and delayed recall (trial 4)

    Time frame: Sept 2022 to October 2026

  6. Non-amnestic cognitive decline

    DSST measure

    Time frame: Sept 2022 to October 2026

  7. White matter microstructure

    Among ppts in the neuromaging subcohort

    Time frame: March 2023 to October 2026

08

Study locations

27 sites
09

References and documents

Related links

Individual participant data

Plan to share: Yes — We will have data in the NACC (National Alzheimer's Coordinating Center) data repository for NACC UDS (Uniform Data Set) data and the rest will be available in the NIDDK data repostiory

Supporting information: Study protocol

Time frame: NACC 2025 and 2027 NIDDK repository 2027

Access criteria: Available to public by application

Data sharing details ↗ · dppos.bsc.gwu.edu

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jan 2027, 50 months after the start.

Of 48 observational studies under Prediabetic State, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 24. This study's planned 50 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2023
First posted
Jan 30, 2023
StartActual
Nov 7, 2022
Primary completionEst.
Jan 31, 2027
CompletionEst.
Aug 30, 2027
Last update
Aug 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05704309
Lead sponsor
Marinella Temprosa
Responsible party
Marinella Temprosa (Principal Investigator, George Washington University) — Sponsor-investigator
First posted
Jan 30, 2023
Start date
Nov 7, 2022
Primary completion
Jan 31, 2027 (estimated)
Completion
Aug 30, 2027 (estimated)
Last update
Aug 26, 2025

Study contacts

Jose Luchsinger
principal investigator · Columbia University
David Nathan
study chair · Massachusetts General Hospital
Marinell Temprosa
principal investigator · George Washington University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion